Cancer Management and Research

Immune Effector Cells for Cancer Therapy – CAR-T and beyond

Cellular therapies for both malignant and non-malignant disease have substantially grown in the past decade. Genetically engineered immune effector cells (IEC) have provided hope for patients with primary refractory malignancies and have received multiple regulatory approvals in B-cell lymphomas, acute lymphoblastic leukemia, and myelomas. Now the investigational portfolio of such promising treatment has grown substantially to include other cellular types (natural killer cells, and tumor infiltrating lymphocytes) and other malignancies including solid tumors.